STX209 (Arbaclofen) for Autism Spectrum Disorders: An 8-Week Open-Label Study
STX209 (arbaclofen), a selective GABA-B agonist, is hypothesized to modulate the balance of excitatory to inhibitory neurotransmission, and has shown preliminary evidence of benefit in fragile X syndrome. We evaluated its safety, tolerability, and efficacy in non-syndromic autism spectrum disorders,...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Other Authors: | , |
Format: | Article |
Language: | English |
Published: |
Springer-Verlag,
2015-03-03T21:25:15Z.
|
Subjects: | |
Online Access: | Get fulltext |